Why We’re Not Veeva (And Why That’s the Point)

Why We’re Not Veeva (And Why That’s the Point)

Let us state this plainly: Veeva, EXTEDO, and Lorenz build excellent products. They serve large pharmaceutical organizations with complex global portfolios, thousands of users, and regulatory operations that span dozens of markets. If you are a top-20 pharma company, those platforms were designed for you.

DnXT was not.

DnXT was built for the company that enterprise RIM vendors tend to overlook — or overcharge. And understanding that distinction is the starting point for a more honest conversation about what mid-size biotech companies actually need from their regulatory technology.

The $300K Problem

Here is a scenario that plays out regularly in the regulatory operations of growing biotech companies.

A company with 100-300 employees is preparing its first or second major submission. The regulatory team is experienced but lean — perhaps 5-15 people. They need publishing capability, document review workflows, and submission planning. These are table-stakes requirements.

They evaluate the established enterprise platforms and encounter a familiar cost structure:

• License fees: $150-400K per year
• Implementation: $200-500K+ with a 6-12 month timeline
• Validation: $50-100K for IQ/OQ/PQ
• Dedicated administration: 1-2 FTEs to manage the platform
• Consulting and configuration: $50-150K to integrate with existing systems

The total cost to get operational frequently exceeds $300K in the first year alone, with ongoing annual costs in the low-to-mid six figures. The implementation timeline means the platform will not be available for the submission that prompted the evaluation in the first place.

This is the $300K problem: enterprise-grade regulatory technology is priced and structured for enterprise-scale organizations. When a 200-person biotech buys the same platform as a 20,000-person pharma company, they are paying for architectural overhead, configurability, and feature breadth that they will never use — while their actual needs go unaddressed for months during implementation.

What Mid-Size Biotech Actually Needs

After hundreds of conversations with regulatory teams at companies between 50 and 500 people, a clear pattern emerges. These teams need three things:

Publishing that works. eCTD compilation, rendering, validation, and gateway submission — executed reliably, with compliance built into the workflow rather than bolted on as a QC step. They do not need a publishing module that is one component of a broader suite. They need publishing that is the core of the platform and works exceptionally well.

Review that is integrated. The ability to route documents for review, collect annotations, manage review cycles, and maintain an audit trail — without exporting files to a separate review tool, emailing PDFs, or managing SharePoint permissions. The review workflow should live where the submission lives.

Planning that provides visibility. A clear view of submission timelines, document readiness, and sequence status across their active programs. Not a full regulatory intelligence suite. Not a global registration database. A planning capability that tells the team where things stand and what needs attention.

These three capabilities — publishing, review, and planning — represent 80-90% of what a mid-size regulatory operation uses on a daily basis. Enterprise RIM platforms deliver these capabilities, but they deliver them alongside dozens of other modules, configuration options, and architectural layers that a 200-person company does not need and cannot fully leverage.

DnXT’s Position: Purpose-Built, Not Scaled Down

DnXT is not a stripped-down enterprise platform. It was built from the ground up for the operational reality of growing life sciences companies. The differences are structural, not cosmetic.

Deploy in weeks, not months. DnXT is a cloud-native platform with a deployment timeline measured in weeks. There is no 6-month implementation project. There is no server infrastructure to provision. Teams can be operational and publishing within their first month, which means the platform is available for the submission that prompted the evaluation — not the one after it.

No dedicated admin required. Enterprise platforms typically require 1-2 full-time administrators to manage configuration, user access, system updates, and integration maintenance. DnXT was designed to be administered by the regulatory team itself. System management is part of the workflow, not a separate function requiring specialized staff.

Transparent pricing. The total cost of an enterprise RIM implementation is notoriously difficult to predict upfront. License fees are negotiated. Implementation scope creeps. Validation costs depend on configuration complexity. DnXT operates on a transparent pricing model where the cost is known before the decision is made — no consulting engagement required to estimate total spend.

Full publishing, review, and planning in one platform. Rather than assembling a tech stack from multiple vendors or licensing a suite where publishing is one module among many, DnXT provides the three core capabilities in a single integrated platform. Publishing is not a feature — it is the foundation, built with the depth required for regulatory submissions across FDA, EMA, Health Canada, and TGA.

Built for 50-500 person companies. The design decisions in DnXT — the user experience, the administrative model, the deployment architecture, the pricing — all reflect the operational reality of companies in this range. This is not a product searching for a market. It is a product built for a market that has been underserved.

Respecting the Landscape

It is important to be direct about what DnXT is not. It is not a full RIM suite. It does not offer the breadth of a platform like Veeva RIM, which provides registration tracking, submission planning at global scale, health authority intelligence, and integrations across the entire regulatory ecosystem. For organizations that need those capabilities — and many do — enterprise platforms are the right choice.

The argument is not that enterprise RIM is bad. The argument is that it is not the only answer, and for a significant number of companies, it is not the right answer.

You should not need a Ferrari to drive to the grocery store. The Ferrari is a remarkable machine. But if your daily requirement is a reliable vehicle that gets you where you need to go efficiently, the Ferrari’s capabilities are not just unnecessary — they are a source of cost and complexity that work against you.

The Decision Framework

When evaluating regulatory technology, the question should not be “which platform has the most features?” It should be “which platform best matches our operational reality — today and over the next 3-5 years?”

For organizations with lean regulatory teams, near-term submission deadlines, and a need for publishing, review, and planning capability that works without a six-figure implementation project, the enterprise path deserves scrutiny. Not because the enterprise platforms are flawed, but because the fit may not be right.

The regulatory technology market has operated for years on the assumption that one tier of solution — the enterprise tier — serves everyone from 50-person biotechs to 50,000-person pharma companies. That assumption is worth questioning.

DnXT exists because we questioned it.